COPD Therapeutics in Major Developed Markets Forecast to year 2021: 1

COPD Therapeutics in Major Developed Markets
to 2021 - Emergence of Addition-in-Class and
First-in-Class Products Offsets Sales Erosion of
Leading Brands
No of Pages – 122
Publishing Date - November 13, 2015
Browse detailed TOC, Tables, Figures, Charts in COPD Therapeutics in Major Developed
Markets to 2021 - Emergence of Addition-in-Class and First-in-Class Products Offsets Sales
Erosion of Leading Brands at- http://www.absolutereports.com/10070564
COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and
First-in-Class Products Offsets Sales Erosion of Leading Brands

Summary

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic
inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of
COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading
cause of death in the world. COPD is linked to cumulative exposure to risk factors, primarily tobacco
smoke, but also environmental pollutants. The COPD marketed products landscape consists of
pharmacological therapies aimed at managing the symptoms associated with COPD, although none
of the available therapies have been shown to modify long-term disease progression.

There are currently 203 products in active development, excluding four with an unknown stage of
development. Although many of the targets identified in the pipeline are well established in the
management of COPD, there are some novel, first-in-class targets. This reflects the growing
understanding of the underlying mechanisms that characterize the disease.

Scope

The COPD market has benefited from notable additions over recent years.